Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 4836

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4836

License Grant
The Company entered into an agreement for the Intellectual Property Rights to Prostaglandin E1 Lyophilized Liposomes for the use of treatment of Psoriasis and other non-sexual dysfunction products.

IPSCIO Record ID: 4104

License Grant
A Canadian University and the Canadian Company entered an agreement for sales of certain products containing prostaglandin E1, and sub-licenses of such products.
License Property
Prostaglandin E1 (PGE1), known pharmaceutically as alprostadil, is a prostaglandin. It is a drug used in the treatment of erectile dysfunction and has vasodilatory properties.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 4898

License Grant
The Company entered into a royalty agreement with the Licensor, an individual, for the intellectual rights to patent, develop, manufacture, and market the LLPGE-1 for the treatment of male erectile dysfunction, impotency and sexual enhancement.
License Property
U.S. Patent 573408: PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction.
Field of Use
The field of use relates to the medical industry.  The Licensee is a development stage biopharmaceutical company whose corporate objective is to utilize medically researched and developed drug substances for sexual dysfunction, determine the ability of these substances to be delivered effectively and determine the potential market for such products.

IPSCIO Record ID: 168983

License Grant
Licensor of Hong Kong grants to Taiwanese Licensee the Exclusive right and license, including the right to grant sublicenses, to make, have made, use and sell the Licensed Product throughout the Territory, as and to the extent such activities are permitted to be conducted in the Territory.
License Property
This product relates to the use of Penetration Enhancement Ingredients in conjunction with Compound A.  Compound A is alprostadil.

Alprostadil, also known as prostaglandin E1 (PGE1), is a naturally occurring prostaglandin which is used as a medication.

Field of Use
'Field' shall mean the development and commercialization of therapeutic products based on proprietary delivery systems including topical treatment products based on a penetration enhancement technology which may enable the active drug/ ingredient to be better absorbed through the skin.

'Indication for Use' shall mean male erectile dysfunction or such other indication for use as parties may agree.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.